Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-EN Version v3-EN
Language English English
Date Updated 2024-11-20 2024-11-01
Drug Identification Number 02499924 02499924
Brand name LEVOTHYROXINE SODIUM INJECTION LEVOTHYROXINE SODIUM INJECTION
Common or Proper name LEVOTHYROXINE SODIUM INJECTION LEVOTHYROXINE SODIUM INJECTION
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients LEVOTHYROXINE SODIUM LEVOTHYROXINE SODIUM
Strength(s) 100MCG 100MCG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR
Packaging sizes (GTIN) (See additional packaging sizes) (See additional packaging sizes)
Additional packaging sizes 5 mL 5 mL
ATC code H03AA H03AA
ATC description THYROID PREPARATIONS THYROID PREPARATIONS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2024-10-31 2024-10-31
Actual start date
Estimated end date 2025-01-15 2025-01-15
Actual end date 2024-11-19
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Levothyroxine Sodium Injection 100 mcg / mL SD Vial 5 mL effective October 31, 2024, until January 15, 2025. As previously communicated, please note that all current inventory is short-dated and expiring October 31, 2024. During this time, our Levothyroxine Sodium for Injection 500 μg SD Vial 10 mL is available as a substitute. Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Levothyroxine Sodium Injection 100 mcg / mL SD Vial 5 mL effective October 31, 2024, until January 15, 2025. As previously communicated, please note that all current inventory is short-dated and expiring October 31, 2024. During this time, our Levothyroxine Sodium for Injection 500 μg SD Vial 10 mL is available as a substitute.
Health Canada comments